{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:02:43Z","timestamp":1790762563407,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00347-026-02474-0","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:16:36Z","timestamp":1784585796000},"page":"761-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Von Phase\u00a0I bis IV\u00a0\u2013 Studiendesigns in der Ophthalmologie richtig verstehen und bewerten","From phase I\u2013IV\u2014Correctly understand and assess study designs in ophthalmology"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-3502","authenticated-orcid":false,"given":"Kristina","family":"Pfau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"N\u00e9meth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"2474_CR1","unstructured":"WMA Declaration of Helsinki \u2013 Ethical Principles for Medical Research Involving Human Subjects \u2013 WMA \u2013 The World Medical Association. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/ Zugregriffen: 25. September, 2023"},{"key":"2474_CR2","unstructured":"AMG - nichtamtliches Inhaltsverzeichnis. https:\/\/www.gesetze-im-internet.de\/amg_1976\/ Zugregriffen: 7. June, 2026"},{"key":"2474_CR3","unstructured":"International council for harmonisation of technical requirements for pharmaceuticals for human use (ICH) (2016) ICH harmonised guideline integrated addendum to ich e6(r1): guideline for good clinical practice e6(r2)."},{"key":"2474_CR4","unstructured":"ISO (2020) ISO 14155:2020 - Clinical investigation of medical devices for human subjects \u2014 Good clinical practice. https:\/\/www.iso.org\/standard\/71690.html. Zugegriffen: 7. Juni 2026"},{"key":"2474_CR5","unstructured":"Step. Committee for Human Medicinal Products (2021) ICH guideline E8 (R1) on general considerations for clinical studies. www.ema.europa.eu\/contact. Zugegriffen: 28. Februar 2026"},{"key":"2474_CR6","unstructured":"International council for harmonisation of technical requirements for pharmaceuticals for human use ich harmonised guideline guideline for good clinical practice E6(R3)"},{"key":"2474_CR7","unstructured":"Fda, Cber (2020) Human Gene Therapy for Retinal Disorders; Guidance for Industry. https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-. Zugegriffen: 28. Februar 2026"},{"key":"2474_CR8","unstructured":"Fda, Cder, Cber. Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment Guidance for Industry DRAFT GUIDANCE. https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-regulatory-information-biologics\/biologics-guidances Zugegriffen: 2. M\u00e4rz, 2026"},{"key":"2474_CR9","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use choice of control group and related issues in clinical trials E10 Current Step 4 version dated (2000) International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use choice of control group and related issues in clinical trials E10 Current Step 4 version dated"},{"issue":"5","key":"2474_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/S00417-017-3890-8\/TABLES\/7","volume":"256","author":"B Eldem","year":"2018","unstructured":"Eldem\u00a0B, Lai\u00a0TYY, Ngah\u00a0NF et\u00a0al (2018) An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology 256(5):963\u2013973. https:\/\/doi.org\/10.1007\/S00417-017-3890-8\/TABLES\/7","journal-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology"},{"issue":"Suppl 1","key":"2474_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/BJOPHTHALMOL-2013-303844","volume":"98","author":"RL Avery","year":"2013","unstructured":"Avery\u00a0RL (2013) What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol 98(Suppl 1):i7. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2013-303844","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"2474_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/14712598.2024.2359015","volume":"24","author":"M Battista","year":"2024","unstructured":"Battista\u00a0M, Carelli\u00a0V, Bottazzi\u00a0L, Bandello\u00a0F, Cascavilla\u00a0ML, Barboni\u00a0P (2024) Gene therapy for Leber hereditary optic neuropathy. Expert Opin Biol Ther 24(6):521\u2013528. https:\/\/doi.org\/10.1080\/14712598.2024.2359015","journal-title":"Expert Opin Biol Ther"},{"issue":"10097","key":"2474_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell\u00a0S, Bennett\u00a0J, Wellman\u00a0JA et\u00a0al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390(10097):849\u2013860. https:\/\/doi.org\/10.1016\/S0140-6736(17)31868-8","journal-title":"Lancet"},{"issue":"2","key":"2474_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3928\/23258160-20140306-08","volume":"45","author":"JB Fileta","year":"2014","unstructured":"Fileta\u00a0JB, Scott\u00a0IU, Flynn\u00a0HW (2014) Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 45(2):143\u2013149. https:\/\/doi.org\/10.3928\/23258160-20140306-08","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"10","key":"2474_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/JAMAOPHTHALMOL.2021.3096","volume":"139","author":"T Li","year":"2021","unstructured":"Li\u00a0T, Sun\u00a0J, Min\u00a0J et\u00a0al (2021) Safety of Receiving Anti-Vascular Endothelial Growth Factor Intravitreal Injection in Office-Based vs Operating Room Settings: A Meta-analysis. JAMA Ophthalmol 139(10):1080\u20131088. https:\/\/doi.org\/10.1001\/JAMAOPHTHALMOL.2021.3096","journal-title":"JAMA Ophthalmol"},{"issue":"9","key":"2474_CR16","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1167\/iovs.17-22339","volume":"58","author":"K Csaky","year":"2017","unstructured":"Csaky\u00a0K, Ferris\u00a0F 3rd, Chew\u00a0EY, Nair\u00a0P, Cheetham\u00a0JK, Duncan\u00a0JL (2017) Report From the NEI\/FDA Endpoints Workshop on Age-Related Macular Degeneration and Inherited Retinal Diseases. Invest Ophthalmol Vis Sci 58(9):3456\u20133463. https:\/\/doi.org\/10.1167\/iovs.17-22339","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2474_CR17","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.ddstr.2012.11.002","volume":"10","author":"LA Lesmes","year":"2013","unstructured":"Lesmes\u00a0LA, Jackson\u00a0L, Bex\u00a0P (2013) Visual Function Endpoints to Enable Dry AMD Clinical Trials. Drug Discov Today Ther Strateg 10(1):e43\u2013e50. https:\/\/doi.org\/10.1016\/j.ddstr.2012.11.002","journal-title":"Drug Discov Today Ther Strateg"},{"issue":"11","key":"2474_CR18","doi-asserted-by":"publisher","DOI":"10.1167\/IOVS.11-7895","volume":"52","author":"RN Weinreb","year":"2011","unstructured":"Weinreb\u00a0RN, Kaufman\u00a0PL (2011) Glaucoma Research Community and FDA Look to the Future, II: NEI\/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: Measures of Structural Change and Visual Function. Invest Ophthalmol Vis Sci 52(11):7842. https:\/\/doi.org\/10.1167\/IOVS.11-7895","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2474_CR19","unstructured":"Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US) (2016) BEST (Biomarkers, EndpointS, and other Tools) Resource. BEST ( Biomarkers , EndpointS , and other Tools ) Resource. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/. Zugegriffen: 2. M\u00e4rz 2026"},{"key":"2474_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.I4919","author":"JA Sterne","year":"2016","unstructured":"Sterne\u00a0JA, Hern\u00e1n\u00a0MA, Reeves\u00a0BC et\u00a0al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https:\/\/doi.org\/10.1136\/BMJ.I4919","journal-title":"BMJ"},{"key":"2474_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne\u00a0JAC, Savovi\u0107\u00a0J, Page\u00a0MJ et\u00a0al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/BMJ.L4898","journal-title":"BMJ"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02474-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02474-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:18:57Z","timestamp":1790759937000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02474-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2474"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02474-0","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.\u00a0Pfau, A.\u00a0Deutsch, R.\u00a0N\u00e9meth, C.\u00a0Fuhrmann und F.G.\u00a0Holz geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}